

**EXPORT LICENSE**

NRC FORM 250  
(10-07)

**UNITED STATES OF AMERICA**  
Nuclear Regulatory Commission  
Washington, D.C. 20555

NRC LICENSE NO.: XMAT444  
Page 1 of 2  
NRC DOCKET NO.: 11006300  
LICENSE EXPIRES June 30, 2023


Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the U.S. Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

<p align="center"><b>LICENSEE</b></p> <p>Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210</p> <p>Attn: Paula Rothwell</p>	<p align="center"><b>ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</b></p> <p align="center">See Page 2</p>
--	---

<p align="center"><b>INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</b></p> <p align="center">NONE</p>	<p align="center"><b>OTHER PARTY(IES) TO EXPORT</b></p> <p align="center">See Page 2</p>
---	--

APPLICANT'S REFERENCE NO.: Appl. date 1/30/18      ULTIMATE DESTINATION(S): Spain

<p align="center"><b>QUANTITY(IES)</b></p> <p>5,000 kilograms</p>	<p align="center"><b>DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)</b></p> <p>Deuterium in the form of deuterium gas, deuterium oxide, and deuterium compounds.</p>
---	---

<p>Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.</p> <p>This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all of the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.</p>	<p align="center"><b>THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVE</b></p> <p>SIGNATURE: <u></u></p> <p>NAME AND TITLE: Peter J. Habighorst, Acting Deputy Director Office of International Programs</p> <p>DATE OF ISSUANCE: <u>06/04/18</u></p>
---	---

**EXPORT LICENSE**



**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

1. Esteve Química, S.A.  
Poligon Industrial, s/n  
17460 Celrà (Girona)  
Spain

(Manufacture active pharmaceutical ingredients for non-nuclear end use in clinical trials for the treatment of cystic fibrosis)

2. Esteve Química, S.A.  
Ctra. Del Vendrell a St. Jaume dels Domenys, km 5  
43711 Banyeres del Penedés (Tarragona)  
Spain

(Manufacture active pharmaceutical ingredients for non-nuclear end use in clinical trials for the treatment of cystic fibrosis)

3. Esteve Química, S.A.  
c/Caracas, 17-19  
08030 Barcelona  
Spain

(Manufacture active pharmaceutical ingredients for non-nuclear end use in clinical trials for the treatment of cystic fibrosis)

**OTHER U.S. PARTY(IES) TO EXPORT:**

1. Cambridge Isotope Laboratories, Inc.  
50 Frontage Road  
Andover, MA 01810

(Supplier/distributor)

2. Aldrich Chemical Co. LLC  
6000 North Teutonia Avenue  
Milwaukee, WI 53209

(Supplier/distributor)

3. Aldrich Chemical Co. LLC  
3858 Benner Road  
Miamisburg, OH 45342

(Supplier/distributor)

4. Sigma Aldrich Fine Chemicals (SAFC)  
5485 County Road V  
Sheboygan Falls, WI 53085

(Supplier/distributor)